메뉴 건너뛰기




Volumn 23, Issue 2, 2013, Pages 78-83

Human pharmacogenetic analysis in chimeric mice with 'humanized livers'

Author keywords

chimeric mice; drug metabolism; pharmacogenetics

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DICLOFENAC; DRUG METABOLITE; MEPHENYTOIN; THYMIDINE KINASE;

EID: 84873097181     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32835cb2c7     Document Type: Article
Times cited : (28)

References (26)
  • 3
    • 84862777541 scopus 로고    scopus 로고
    • A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
    • Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483:613-617.
    • (2012) Nature , vol.483 , pp. 613-617
    • Chen, Z.1    Cheng, K.2    Walton, Z.3    Wang, Y.4    Ebi, H.5    Shimamura, T.6
  • 5
    • 62249183036 scopus 로고    scopus 로고
    • Predicting circulating human metabolites: How good are we?
    • Anderson S, Luffer-Atlas D, Knadler MP. Predicting circulating human metabolites: how good are we? Chem Res Toxicol 2009; 22:243-256.
    • (2009) Chem Res Toxicol , vol.22 , pp. 243-256
    • Anderson, S.1    Luffer-Atlas, D.2    Knadler, M.P.3
  • 6
    • 70350243185 scopus 로고    scopus 로고
    • A holistic strategy for characterizing the safety of metabolites through drug discovery and development
    • Walker D, Brady J, Dalvie D, Davis J, Dowty M, Duncan JN, et al. A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem Res Toxicol 2009; 22:1653-1662.
    • (2009) Chem Res Toxicol , vol.22 , pp. 1653-1662
    • Walker, D.1    Brady, J.2    Dalvie, D.3    Davis, J.4    Dowty, M.5    Duncan, J.N.6
  • 7
    • 62249142787 scopus 로고    scopus 로고
    • Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development
    • Leclercq L, Cuyckens F, Mannens GS, de Vries R, Timmerman P, Evans DC. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem Res Toxicol 2009; 22:280-293.
    • (2009) Chem Res Toxicol , vol.22 , pp. 280-293
    • Leclercq, L.1    Cuyckens, F.2    Mannens, G.S.3    De Vries, R.4    Timmerman, P.5    Evans, D.C.6
  • 9
    • 70449090414 scopus 로고    scopus 로고
    • In vivo modeling of human liver for pharmacological study using humanized mouse
    • Yoshizato K, Tateno C. In vivo modeling of human liver for pharmacological study using humanized mouse. Expert Opin Drug Metab Toxicol 2009; 5:1435-1446.
    • (2009) Expert Opin Drug Metab Toxicol , vol.5 , pp. 1435-1446
    • Yoshizato, K.1    Tateno, C.2
  • 10
    • 77949750816 scopus 로고    scopus 로고
    • New Horizons for studying human hepatotropic infections
    • De Jong YP, Rice CM, Ploss A. New Horizons for studying human hepatotropic infections. J Clin Invest 2010; 120:650-653.
    • (2010) J Clin Invest , vol.120 , pp. 650-653
    • De Jong, Y.P.1    Rice, C.M.2    Ploss, A.3
  • 11
    • 18344410760 scopus 로고    scopus 로고
    • NOD/SCID/gamma (c)(null) mouse: An excellent recipient mouse model for engraftment of human cells
    • Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD/SCID/gamma (c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100:3175-3182.
    • (2002) Blood , vol.100 , pp. 3175-3182
    • Ito, M.1    Hiramatsu, H.2    Kobayashi, K.3    Suzue, K.4    Kawahata, M.5    Hioki, K.6
  • 12
    • 84872743384 scopus 로고    scopus 로고
    • Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction
    • press
    • Nishimura T, Hu Y, Wu M, Pham E, Suemizu H, Elazar M, et al. Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther 2012 (in press).
    • (2012) J Pharmacol Exp Ther
    • Nishimura, T.1    Hu, Y.2    Wu, M.3    Pham, E.4    Suemizu, H.5    Elazar, M.6
  • 14
    • 0036394942 scopus 로고    scopus 로고
    • Clinical significance of the cytochrome P450 2C19 genetic polymorphism
    • Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41:913-958.
    • (2002) Clin Pharmacokinet , vol.41 , pp. 913-958
    • Desta, Z.1    Zhao, X.2    Shin, J.G.3    Flockhart, D.A.4
  • 15
    • 79960613122 scopus 로고    scopus 로고
    • Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy
    • Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011; 90:328-332.
    • (2011) Clin Pharmacol Ther , vol.90 , pp. 328-332
    • Scott, S.A.1    Sangkuhl, K.2    Gardner, E.E.3    Stein, C.M.4    Hulot, J.S.5    Johnson, J.A.6
  • 16
    • 0034752109 scopus 로고    scopus 로고
    • CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase
    • Zhou HH. CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase. Clin Chim Acta 2001; 313:203-208.
    • (2001) Clin Chim Acta , vol.313 , pp. 203-208
    • Zhou, H.H.1
  • 17
    • 0036263813 scopus 로고    scopus 로고
    • Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data
    • Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12:251-263.
    • (2002) Pharmacogenetics , vol.12 , pp. 251-263
    • Lee, C.R.1    Goldstein, J.A.2    Pieper, J.A.3
  • 18
    • 0141791128 scopus 로고    scopus 로고
    • Cytochrome P450 enzyme polymorphisms and adverse drug reactions
    • Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003; 192:23-32.
    • (2003) Toxicology , vol.192 , pp. 23-32
    • Pirmohamed, M.1    Park, B.K.2
  • 20
    • 0025005022 scopus 로고
    • Induction of polymorphic 4-hydroxylation of S-mephenytoin by rifampicin
    • Zhou HH, Anthony LB, Wood AJ, Wilkinson GR. Induction of polymorphic 4-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 1990; 30:471-475.
    • (1990) Br J Clin Pharmacol , vol.30 , pp. 471-475
    • Zhou, H.H.1    Anthony, L.B.2    Wood, A.J.3    Wilkinson, G.R.4
  • 22
    • 0034074957 scopus 로고    scopus 로고
    • Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9&z.ast;3 allele
    • Shimamoto J, Ieiri I, Urae A, Kimura M, Irie S, Kubota T, et al. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9&z.ast;3 allele. Eur J Clin Pharmacol 2000; 56:65-68.
    • (2000) Eur J Clin Pharmacol , vol.56 , pp. 65-68
    • Shimamoto, J.1    Ieiri, I.2    Urae, A.3    Kimura, M.4    Irie, S.5    Kubota, T.6
  • 23
    • 0346784817 scopus 로고    scopus 로고
    • Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: No relationship to the CYP2C9 genetic polymorphism in humans
    • Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 2003; 55:51-61.
    • (2003) Br J Clin Pharmacol , vol.55 , pp. 51-61
    • Kirchheiner, J.1    Meineke, I.2    Steinbach, N.3    Meisel, C.4    Roots, I.5    Brockmoller, J.6
  • 24
    • 62249093071 scopus 로고    scopus 로고
    • Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites
    • Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, et al. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 2009; 22:357-368.
    • (2009) Chem Res Toxicol , vol.22 , pp. 357-368
    • Dalvie, D.1    Obach, R.S.2    Kang, P.3    Prakash, C.4    Loi, C.M.5    Hurst, S.6
  • 25
    • 84856007232 scopus 로고    scopus 로고
    • The promise of induced pluripotent stem cells in research and therapy
    • Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature 2012; 481:295-305.
    • (2012) Nature , vol.481 , pp. 295-305
    • Robinton, D.A.1    Daley, G.Q.2
  • 26
    • 79955904906 scopus 로고    scopus 로고
    • In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins
    • Liu H, Kim Y, Sharkis S, Marchionni L, Jang YY. In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci Transl Med 2011; 3:82ra39.
    • (2011) Sci Transl Med , vol.3
    • Liu, H.1    Kim, Y.2    Sharkis, S.3    Marchionni, L.4    Jang, Y.Y.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.